Advances in Urology / 2012 / Article / Tab 1

Research Article

The Role of Adjuvant Hormonal Treatment after Surgery for Localized High-Risk Prostate Cancer: Results of a Matched Multiinstitutional Analysis

Table 1

Preoperative and postoperative characteristics of the 172 matched patients.

CharacteristicGroup 1Group 2
Adjuvant ADTNo adjuvant ADT

Patients number8686
Median age (years)66.266.6
Median Follow-up (months)6966
Mean PSA, ng/mL (range)31.5 (3–119)28.4 (2.78–159)

Clinical stage, 1997 TNM, (number (%))
 ≤cT236 (41.8%)48 (55.8%)
 cT349 (57.0% )37 (43.0%)
 cT41 (1.2 %)1 (1.2%)

Biopsy Gleason score (number (%))
 ≤636 (41.8%)44 (51.2%)
  739 (45.3%)32 (37.2%)
 ≥811 (12.9%)10 (11.6%)

Pathol. stage, 1997 TNM (number (%))
 pT24 (4.7%)9 (10.5%)
 pT3a28 (32.5%)29 (33.7%)
 pT3b50 (58.1%)45 (52.3%)
 pT44 (4.7%)3 (3.5%)

Pathol. Gleason score (number (%))
 ≤634 (39.5%)34 (39.5%)
 739 (45.4%)39 (45.4%)
 ≥813 (15.1%)13 (15.1%)

Surgical margins (number (%))
 Positive62 (72.1%)66 (76.7%)
 Negative24 (27.9%)20 (23.3%)

Salvage therapy
 ADT0 (0.0%)25 (29.1%)
 Radiotherapy3 (3.5%)9 (10.5%)

PSA: prostate-specific antigen; ADT: androgen deprivation therapy.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.